Navigation Links
MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Date:7/31/2012

aws of any such state or other jurisdiction.

About MAP Pharmaceuticals

MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. 

Forward-Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to our expectations regarding the completion of the proposed public offering. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include, without limitation, risks and uncertainties related to whether or not we will be able to raise capital through the sale of shares of common stock, the final terms of the proposed offering, market and other conditions, the satisfaction of customary closing conditions related to the proposed public offering and the impact of general economic, industry or political conditions in the United States or internationally. There can be no assurance that we will be able to complete the proposed public offering on the anticipated terms, or at all. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. Additional risks and uncertainties relating to the proposed offering, MAP Pharmaceuticals and our business can be found under the heading "Risk Factors" in our most recent Form 10-Q filed with the SEC, in other filings that we periodically make with the SEC, and in the preliminary prospectus supplement related to the proposed offering to be filed with the SEC on the date hereof. In addition, the forward-looking statements included in this press release represent our views as of the date of this press release. We anticipate that subsequent events a
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
3. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
4. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
7. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
8. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
9. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
10. WuXi PharmaTech Announces Third-Quarter 2011 Results
11. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... independent, predictor of heart attack and stroke ... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a worldwide developer ... be exhibiting its,AspirinWorks(R) Test November 9 - 11 in ... 2008 in New Orleans, La., New CHARISMA trial ...
... EDMONTON, Nov. 5 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: ... today,announced that Mr. Kevin Giese, President and CEO, will present ... York., WHEN: Monday November ... New York Palace Hotel, New York., About BioMS Medical ...
... Calif., Nov. 5 Neurobiological,Technologies, Inc. (Nasdaq: NTII ... Executive Officer, will present at the Rodman & Renshaw,10th ... New York Palace,Hotel., Mr. Freiman,s presentation will take ... presentation will be webcast and can be accessed by ...
Cached Biology Technology:Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting 2Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting 3BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference 2
(Date:7/11/2014)... the proteins that let nerve cells send out electrical ... a biological tactic that may offer a new way ... and environmentally responsible way. , Their findingthat naturally ... and harmless for a closely related onesuggests that insecticides ... beneficial species like bees. A summary of the research, ...
(Date:7/10/2014)... Mass. , June 30, 2014  Aware, Inc. ... biometrics software and services, previously announced on June 26, ... special cash dividend of $1.75 per share, or approximately ... date of July 10, 2014 and a payment date ... by NASDAQ that it had set an ex-dividend date ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... with colleagues in Sweden and abroad, have identified an entirely ... inhibits formation of new blood vessels. Inhibiting the formation of ... cancer treatment. The study is published in the November issue ... the formation of new blood vessels, is strictly regulated by ...
... the number of weeks of pregnancy, due to associated problems ... brain damage can result. The condition, known as Intra-uterine ... a baby,s health and determine the best time for delivery. ... had to rely on educated guesses about the strength of ...
... MADISON, WI, NOVEMBER 9, 2009 -- Agricultural ... a result of their presence in wastes (sewage biosolids ... periods of time. Regulations and guidelines for tolerable concentrations ... on the assumption that the toxic effects of the ...
Cached Biology News:New mechanism explains how the body prevents formation of blood vessels 2Healthy babies by the numbers 2Additive copper-zinc interaction affects toxic response in soybean 2
MpV17 transgene, murine homolog, glomerulosclerosis...
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
Biology Products: